02:47 , Feb 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Expansion into TNBC

With an RNA-binding small molecule that sensitizes HER2-negative cancers to Herceptin, Matt Disney’s latest study adds to the growing arsenal of preclinical therapies against triple-negative breast cancer. The only problem is the molecule may run...
00:38 , Feb 8, 2019 |  BC Innovations  |  Product R&D

Reducing R(i)SK in TNBC

Phoenix Molecular Designs could provide triple-negative breast cancer its first molecular marker to turn the intractable indication from a group of have-nots to a group of haves. With early evidence that RSK2 is activated in...
20:04 , Jan 18, 2019 |  BC Week In Review  |  Company News

Phoenix, Roche partner to develop TNBC biomarker

Phoenix Molecular Designs (Vancouver, B.C.) and Roche (SIX:ROG; OTCQX:RHHBY) partnered on Jan. 16 to develop a molecular diagnostic to help stratify triple-negative breast cancer patients. Roche will develop an assay to detect activation of RPS6KA3,...
00:53 , Jan 17, 2019 |  BC Extra  |  Company News

Phoenix, Roche partner to develop TNBC biomarker

Phoenix Molecular Designs (Vancouver, B.C.) and Roche (SIX:ROG; OTCQX:RHHBY) partnered on Wednesday to develop a molecular diagnostic to help stratify triple-negative breast cancer patients. Roche will develop an assay to detect activation of RPS6KA3, which...
16:35 , Jul 20, 2018 |  BC Week In Review  |  Financial News

Hotspot debuts with $45M to find, drug natural allosteric sites

HotSpot Therapeutics Inc. (Cambridge, Mass.) emerged from stealth on July 17 with a $45 million series A round co-led by Atlas Venture and Sofinnova Partners. The company is developing small molecule therapies that imitate natural...
21:58 , Jul 17, 2018 |  BC Innovations  |  Product R&D

Natural spots

With a new take on allosteric modulation, HotSpot Therapeutics Inc. has emerged from stealth mode to find specialized niches on proteins that nature uses to control their activity. The company’s platform has identified druggable allosteric...
11:00 , Jul 17, 2018 |  BC Extra  |  Financial News

HotSpot debuts with $45M to find, drug natural allosteric sites

HotSpot Therapeutics Inc. (Cambridge, Mass.) emerged from stealth on Tuesday with a $45 million series A round co-led by Atlas Venture and Sofinnova Partners. The company is developing small molecule therapies that imitate natural forms...
17:01 , Jan 31, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers Tumor levels of RPS6KA5 could help predict survival in ESR1-positive breast cancer. In 193 patients, low primary tumor levels of RPS6KA5 mRNA were associated with poor metastasis-free survival. In another 214 patients,...
19:27 , Sep 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Spinal cord injury (SCI) Mouse studies suggest inhibiting RPS6KB1 could help treat SCI. In a mouse model of SCI, intracortical injection of a selective RPS6KB1 inhibitor tool compound increased regeneration of the cortico-spinal tract...
20:11 , Jul 27, 2017 |  BC Extra  |  Preclinical News

Group identifies S6K1 as potential target for CNS injury

In a paper published in the Journal of Neuroscience , researchers at the University of Miami Miller School of Medicine and colleagues showed that targeting ribosomal protein S6 kinase 70kDa polypeptide 1 ( RPS6KB1 ;...